Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Other hematologic neoplasm 7Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 3Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Carotid Intimal Medial Thickness 1 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pioglitazone × Dermatologic × Clear all
NCT02347813 2020-06-23

Preventing Squamous Cell Skin Cancer

University of Rochester

Phase 2 Completed
12 enrolled 10 charts
Dermatologic

Carotid Intimal Medial Thickness 1, Carcinoma, Squamous Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡